Merck & Co and Pfizer join forces on diabetes pill

New Drug Approvals

ertugliflozin

PF04971729

(1S,2S,3S,4R,5S)-5-[4-Chloro-3-(4-ethoxybenzyl)phenyl]-1-(hydroxymethyl)-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triol

Drug giants Merck & Co and Pfizer have formed a new alliance to jointly develop and commercialise the latter’s ertugliflozin for the treatment of type II diabetes.

The drug is an investigational oral sodium glucose cotransporter (SGLT2) inhibitor, which is on the verge of entering Phase III trials, scheduled for later this year.

read more

http://www.pharmatimes.com/Article/13-04-30/Merck_Co_and_Pfizer_join_forces_on_diabetes_pill.aspx

View original post

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s